Combination therapy in inflammatory bowel disease patients: do we need to maximize the dose of azathioprine?

References

• Lamb CA, Kennedy NA, Raine T, IBD Guidelines eDelphi Consensus Group, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–s106.
   PubMed Web of Science ®Google Scholar
• Cholapranee A, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45(10):1291–1302.
   PubMed Web of Science ®Google Scholar
• Shah SC, Colombel J-F, Sands BE, et al. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease. Aliment Pharmacol Ther. 2016;43(3):317–333.
   PubMed Web of Science ®Google Scholar
• Chaparro MB-d, Echarri A, Almendros R, et al. Correlation between anti-TNF serum levels and endoscopic inflammation in inflammatory bowel disease patients. Dig Dis Sci. 2019;64(3):846–854.
   PubMed Web of Science ®Google Scholar
• Greuter T, Maillard MH, Juillerat P, et al. Therapeutic drug monitoring to guide clinical decision making in inflammatory bowel disease patients with loss of response to anti-TNF: a delphi technique-based consensus. Digestion. 2019:1–9.
   PubMed Web of Science ®Google Scholar
• Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn's disease: medical treatment. J Crohns Colitis. 2020;14(1):4–22.
   PubMed Web of Science ®Google Scholar
• Singh S, George J, Boland BS, et al. Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis. J Crohns Colitis. 2018;12(6):635–643.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Adedokun OJ, Gasink C, et al. Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a *post hoc analysis. Clin Gastroenterol Hepatol. 2019;17(8):1525–1532 e1.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362(15):1383–1395.
   PubMed Web of Science ®Google Scholar
• Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392–400 e3.
   PubMed Web of Science ®Google Scholar
• Bots S, Gecse K, Barclay M, et al. Combination immunosuppression in IBD. Inflamm Bowel Dis. 2018;24(3):539–545.
   PubMed Web of Science ®Google Scholar
• Gong SS, Fan YH, Han QQ, et al. Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease. World J Gastroenterol. 2019;25(18):2240–2250.
   PubMed Web of Science ®Google Scholar
• Singh S, Facciorusso A, Dulai PS, et al. Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020;18(1):69–81 e3.
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, European Crohn’s and Colitis Organization [ECCO], et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–784.
   PubMed Web of Science ®Google Scholar
• Polakovicova V, Kadleckova B, Lucenicova J, et al. Positive pharmacokinetic effect of azathioprine co-medication on infliximab trough levels is dose-dependent. Dig Liver Dis. 2019;51(8):1112–1116.
   PubMedGoogle Scholar
• Roblin X, Williet N, Boschetti G, et al. Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial. Gut. 2020;69(7):1206–1212.
   PubMed Web of Science ®Google Scholar
• Sparrow MP, Papamichael K, Ward MG, et al. Therapeutic drug monitoring of biologics during induction to prevent primary non-response. J Crohns Colitis. 2019;14:542–556.
   Web of Science ®Google Scholar
• Steenholdt C, Bendtzen K, Brynskov J, et al. Optimizing treatment with TNF inhibitors in inflammatory bowel disease by monitoring drug levels and antidrug antibodies. Inflamm Bowel Dis. 2016;22(8):1999–2015.
   PubMed Web of Science ®Google Scholar
• Matar M, Shamir R, Turner D, et al. Combination therapy of adalimumab with an immunomodulator is not more effective than adalimumab monotherapy in children with Crohn's disease: a post hoc analysis of the PAILOT randomized controlled trial. Inflamm Bowel Dis. 2019;izz294. DOI: 10.1093/ibd/izz294.
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Motoya S, Watanabe K, DIAMOND Study Group, et al. Adalimumab monotherapy and a combination with azathioprine for Crohn's disease: a prospective, randomized trial. J Crohns Colitis. 2016;10(11):1259–1266.
   PubMed Web of Science ®Google Scholar
• Holmer A, Singh S. Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases. Expert Rev Clin Immunol. 2019;15(9):969–979.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107(7):1051–1063.
   PubMed Web of Science ®Google Scholar
• Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134(4):929–936.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Brousse N, Bouvier AM, CESAME Study Group, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–1625.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141(5):1621–1628.
   PubMed Web of Science ®Google Scholar
• Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318(17):1679–1686.
   PubMed Web of Science ®Google Scholar